Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: An individual patient data (IPD) analysis

Marina Chiara Garassino, Tomoya Kawaguchi, Vanesa Gregorc, Eliana Rulli, Masahiko Ando, Silvia Marsoni, Shun Ichi Isa, Silvia Novello, Gabriella Farina, Sandro Barni, Valter Torri, Michela Cinquini

Research output: Contribution to journalArticle

Abstract

The efficacy of second-line treatment in patients with epidermal growth factor receptor (EGFR) wild-type tumours is still debatable. We assessed the efficacy of a standard second-line chemotherapy compared with erlotinib in an individual patient data approach for meta-analysis. The primary endpoint was overall survival (OS), and secondary endpoint was progression-free survival (PFS). Both were compared by log-rank test. The 'restricted mean survival time' (RMST) was estimated in each study and the difference in mean survival time up to the last available time point was calculated. The Cox proportional hazards model was used on survival analyses to provide HRs, to adjust for confounding variables and to test possible interaction with selected factors. Three randomised trials comparing chemotherapy versus erlotinib were analysed, including 587 randomised patients. Overall, 74% of patients included in the original trials were considered. 464 deaths and 570 progressions or deaths were observed. Compared with erlotinib, chemotherapy was associated to a decreased risk of progression (29%; HR: 0.71, 95% CI: 0.60 to 0.84, p< 0.0001;) but with no statistical significant reduction in OS (HR: 0.89, 95% CI: 0.74 to 1.06; p<0.20). No heterogeneity was found in both analyses. Patients treated with chemotherapy gained an absolute 1.5 and 1.6 months, respectively, in PFS and lifetime (RMST 95% CI: PFS 0.49 to 2.44; OS 95% CI: -1.04 to 4.25). These results showed that patients without a constitutively activated EGFR had better PFS with chemotherapy rather than with erlotinib while no statistical difference was observed in OS.

Original languageEnglish
Article numbere000327
JournalESMO Open
Volume3
Issue number6
DOIs
Publication statusPublished - Oct 1 2018

Keywords

  • erlotinib
  • independent patients' data (IPD)
  • non-small cell lung cancer (NSCLC)
  • wild-type epidermal growth factor receptor (wt-EGFR)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: An individual patient data (IPD) analysis'. Together they form a unique fingerprint.

  • Cite this

    Garassino, M. C., Kawaguchi, T., Gregorc, V., Rulli, E., Ando, M., Marsoni, S., Isa, S. I., Novello, S., Farina, G., Barni, S., Torri, V., & Cinquini, M. (2018). Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: An individual patient data (IPD) analysis. ESMO Open, 3(6), [e000327]. https://doi.org/10.1136/esmoopen-2018-000327